1. Home
  2. ARKO vs DRUG Comparison

ARKO vs DRUG Comparison

Compare ARKO & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ARKO Corp.

ARKO

ARKO Corp.

HOLD

Current Price

$5.69

Market Cap

608.8M

Sector

Energy

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$89.46

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARKO
DRUG
Founded
1970
2019
Country
United States
United States
Employees
9748
N/A
Industry
Oil Refining/Marketing
Pharmaceuticals and Biotechnology
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
608.8M
707.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ARKO
DRUG
Price
$5.69
$89.46
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$7.50
$129.25
AVG Volume (30 Days)
999.8K
137.4K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
2.15%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.86
N/A
Revenue Next Year
$1.49
N/A
P/E Ratio
$56.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.71
$23.18
52 Week High
$6.71
$123.75

Technical Indicators

Market Signals
Indicator
ARKO
DRUG
Relative Strength Index (RSI) 53.55 67.86
Support Level $4.80 $69.83
Resistance Level $6.65 $91.00
Average True Range (ATR) 0.23 5.25
MACD 0.03 2.11
Stochastic Oscillator 61.03 96.27

Price Performance

Historical Comparison
ARKO
DRUG

About ARKO ARKO Corp.

ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: